Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Calquence
Pharma
Lilly's Jaypirca blazes CLL trail with FDA approval
The ability to help patients who have failed on a BTK inhibitor makes Jaypirca unique compared to existing covalent BTK agents for CLL.
Angus Liu
Dec 4, 2023 4:11am
Questions swirl around AstraZeneca's cancer drugs
Nov 9, 2023 11:39am
NICE signs off on AbbVie, J&J's Imbruvica-Venclyxta combo in CLL
Apr 21, 2023 11:30am
Abbvie, J&J pull 2 Imbruvica accelerated approvals
Apr 7, 2023 10:25am
AZ CEO honors $40B revenue goal, touts 15 new drugs by 2030
Feb 9, 2023 11:00am
BeiGene's Brukinsa snags key leukemia nod in heated BTK fight
Jan 20, 2023 10:20am